Entries |
Document | Title | Date |
20100331247 | PEPTIDE THERAPY FOR HYPERGLYCEMIA - Methods of modulating blood glucose levels treating hyperglycemia and related complications and conditions by administration of a VGF biomolecule to a patient in need of such treatment are provided. Methods of enhancing insulin secretion from islet beta cells in a mammal exhibiting reduced insulin secretion by administration of a therapeutically effective amount of a VGF biomolecule are also provided. | 12-30-2010 |
20110059888 | METASTIN DERIVATIVES AND USE THEREOF - The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotropic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids, the metastin derivatives of the present invention achieve more improved blood stability, solubility, etc., reduced gelation tendency, improved pharmacokinetics, as well as exhibit an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity. The metastin derivatives of the present invention also have a gonadotropic hormone secretion suppressing activity, sex hormone secretion suppressing activity, etc. | 03-10-2011 |
20110124554 | Fibrosuppressant Biotherapeutics - The invention relates to IHG-1 (induced by high glucose-1) a novel gene which encodes a protein that amplifies fibrotic responses in in vitro and in vivo models of fibrotic disorders and in human diabetic nephropathy. In particular the invention relates to modifications of the IHG-1 structure which are potential fibrosuppressant biotherapeutics and modify cellular invasiveness. The invention also relates to a method of screening a therapeutic agent for suitability for the treatment of fibrotic disease comprising testing a candidate therapeutic agent for the ability to reduce the expression of IHG-1 levels in a model system. | 05-26-2011 |
20110124555 | USE OF SOMATOSTATIN ANALOGS IN CONTROL OF HYPOGLYCEMIA - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the control of hypoglycemia. | 05-26-2011 |
20110190200 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL pH BUFFERS - Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs. | 08-04-2011 |
20110212890 | METASTIN DERIVATIVE AND USE THEREOF - Disclosed is a stable metastin derivative having excellent biological activities (e.g., a cancer metastasis inhibiting activity, a cancer proliferation inhibiting activity, a gonadotropin secretion promoting activity, a sex hormone secretion promoting activity). A metastin derivative produced by substituting a constituent amino acid in metastin can be improved in stability in the blood and can have an excellent cancer metastasis inhibiting activity, an excellent cancer proliferation inhibiting activity, an excellent gonadotropin secretion inhibiting activity, an excellent sex hormone secretion inhibiting activity and the like by binding the metastin derivative to polyethylene glycol. | 09-01-2011 |
20110281796 | NOVEL ACTIVIN RECEPTOR AND USES THEREOF - The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided. | 11-17-2011 |
20120046225 | STABLE GLUCAGON FORMULATIONS FOR THE TREATMENT OF HYPOGLYCEMIA - The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated form of injectable glucagon that is dissolved in a pharmaceutically acceptable carrier. | 02-23-2012 |
20130029906 | METHOD OF REGULATING PPAR, OBESITY RELATED PATHWAYS AND THEIR ASSOCIATED METABOLIC IMPACT - It is disclosed a method of modulating a peroxisome proliferator activated receptor (PPAR) activity in a patient comprising administering to said subject an effective amount of a malleable protein matrix (MPM), uses thereof and pharmaceutical compositions comprising MPM for treating obesity related disorders and their associated metabolic impact by modulating PPAR activity. | 01-31-2013 |
20130303447 | METHODS FOR PREVENTING OR TREATING INSULIN RESISTANCE - The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 11-14-2013 |
20130310313 | POLYPEPTIDES, NUCLEIC ACID MOLECULE ENCODING POLYPEPTIDES, AND USES OF POLYPEPTIDES - A polypeptide, a nucleic acid molecule encoding the polypeptide and a pharmaceutical composition comprising the polypeptide are provided. The polypeptide is as defined in the description, can bind to insulin receptors, and is effective in reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes. | 11-21-2013 |
20130331322 | EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITY - Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents. | 12-12-2013 |
20140088003 | POLYMER-BASED SUSTAINED RELEASE DEVICE - This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | 03-27-2014 |
20140171364 | STABLE GLUCAGON FORMULATIONS FOR THE TREATMENT OF HYPOGLYCEMIA - The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated form of injectable glucagon that is dissolved in a pharmaceutically acceptable carrier. | 06-19-2014 |
20140179599 | STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS - Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations. | 06-26-2014 |
20140179600 | STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS - Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations. | 06-26-2014 |
20140371142 | MYONECTIN (CTRP15), COMPOSITIONS COMPRISING SAME, AND METHODS OF USE - Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making antibodies to the myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and/or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt/mTOR pathway is also provided. | 12-18-2014 |
20150359839 | METHODS FOR PREVENTING OR TREATING INSULIN RESISTANCE - The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 12-17-2015 |
20150374782 | SOLID COMPOSITION - Provided is a solid composition which has reduced bad taste and offensive odor and provides good taste and flavor, while containing wheat albumin at a high concentration. A solid composition comprising the following components (A) and (B): (A) wheat albumin, and (B) alanine or a salt thereof, wherein a mass ratio of a content of the 0.19-wheat albumin (a) in the solid composition to a content of the alanine or a salt thereof in terms of alanine (b) in the solid composition, [(a):(b)], is from 250:1 to 10:1. | 12-31-2015 |
20160184388 | Use of Somatostatin Analogs in Control of Hypoglycemia - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the control of hypoglycemia. | 06-30-2016 |
20160194355 | DIPEPTIDYL PEPTIDASE-IV (DPPIV), INHIBITORY PEPTIDE COMPOUND, COMPOSITION CONTAINING THE SAME, AND PRODUCTION METHOD FOR THE SAME | 07-07-2016 |